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Background
Studies suggest that rates of anaphylaxis, the most severe
form of an allergic reaction, are increasing in Pediatric
Emergency Departments (PED). Significant gaps still exist
regarding the prevalence, triggers and temporal trends of
anaphylaxis in Canada. The Cross-Canada Anaphylaxis
Registry (C-CARE) was created with the primary goal of
determining the societal burden of anaphylaxis in Canada;
our aim was to use C-CARE to examine temporal trends
in anaphylaxis rates.
Methods
Over a 2-year period (April 2011 to April 2013), children
presenting to the Montreal Children’s Hospital PED
with anaphylaxis were recruited. The treating physician
documented characteristics and triggers of anaphylactic
reactions using a standardized data entry form. Charts of
all PED patients were reviewed to identify anaphylactic
cases that were missed in prospective recruitment.
Results
Among 81,677 PED visits in Year 1, 168 anaphylaxis cases
were identified (0.21%) versus 218 anaphylaxis cases
among 78,650 PED visits in Year 2 (0.27%), yielding a
difference of 0.06% (95% CI, 0.02%, 0.12%) between the
two years. The median age of anaphylaxis was 4.8 years
(IQR: 2.3-10.1) in Year 1 and 5.9 years (IQR 2.1-11.1) in
Year 2. There was a slightly higher male predominance in
cases of anaphylaxis in both Year 1 (51.8%; 95% CI, 44%,
59.5%) and Year 2 (61%; 95% CI, 54.2%, 67.4%). The major
triggers in both years were food allergens (87.5% and
80.6% respectively) with peanut being the most predomi-
nant (29.5% and 20.6%) followed by tree nuts (15.5% and
14.8%). Severe anaphylaxis (hypoxia, cyanosis, circulatory
collapse, incontinence or neurological symptoms) was
found in 7.1% (95% CI, 3.9%, 12.4%) of patients from
Year 1 versus 3.7% (95% CI, 1.7%, 7.4%) in Year 2.
Conclusions
There was a greater rate of anaphylaxis in the second year
of the C-CARE study. In both years, food allergens were
found to be the most common trigger with peanuts being
the most common food. These results are comparable to
the increasing rates of anaphylaxis seen in other wester-
nized countries. Future studies in the Montreal Children’s
Hospital as well as in other centers are required to estab-
lish temporal trends in anaphylaxis rates, triggers and
reaction characteristics.
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